{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:55:19Z","timestamp":1789995319091,"version":"4.0.1"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,4,15]]},"abstract":"<jats:p> PURPOSE: Rituximab has been reported to have little activity in small lymphocytic lymphoma (SLL)\/chronic lymphocytic leukemia (CLL) and to be associated with significant infusion-related toxicity. This study sought to decrease the initial toxicity and optimize the pharmacokinetics with an alternative treatment schedule. <\/jats:p><jats:p> PATIENTS AND METHODS: Thirty three patients with SLL\/CLL received dose 1 of rituximab (100 mg) over 4 hours. In cohort I (n = 3; 250 mg\/m<jats:sup>2<\/jats:sup>) and cohort II (n = 7; 375 mg\/m<jats:sup>2<\/jats:sup>) rituximab was administered on day 3 and thereafter three times weekly for 4 weeks using a standard administration schedule. Cohort III (n = 23; 375 mg\/m<jats:sup>2<\/jats:sup>) administered rituximab similar to cohort II for the first two treatments and then over 1 hour thereafter. <\/jats:p><jats:p> RESULTS: A total of 33 CLL\/SLL patients were enrolled; only one patient discontinued therapy because of infusion-related toxicity. Thirteen patients developed transient hypoxemia, hypotension, or dyspnea that were associated with significant changes in baseline interleukin-6, interleukin-8, tumor necrosis factor alpha, and interferon gamma compared with those not experiencing such reactions. Infusion-related toxicity occurred more commonly in older (median age 73 v 62 years; P = .02) patients with no other pretreatment clinical or laboratory features predicting occurrence of these events. The overall response rate was 45% (3% CR, 42% PR; 95% CI 28% to 64%). Median response duration for these 15 patients was 10 months (95% CI, 6.8-13.2; range, 3 to 17+). <\/jats:p><jats:p> CONCLUSION: Rituximab administered thrice weekly for 4 weeks demonstrates clinical efficacy and acceptable toxicity. Initial infusion-related events seem to be cytokine mediated and resolve by the third infusion making rapid administration possible. Future combination studies of rituximab with other therapies in CLL seem warranted. <\/jats:p>","DOI":"10.1200\/jco.2001.19.8.2153","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:37:31Z","timestamp":1487918251000},"page":"2153-2164","source":"Crossref","is-referenced-by-count":407,"title":["Rituximab Using A Thrice Weekly Dosing Schedule in  B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity"],"prefix":"10.1200","volume":"19","author":[{"given":"John C.","family":"Byrd","sequence":"first","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Murphy","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin S.","family":"Howard","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret S.","family":"Lucas","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Goodrich","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Park","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pearson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie K.","family":"Waselenko","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Ling","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio J.","family":"Grillo-Lopez","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Kunkel","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore; Department of Critical Care Medicine, Uniformed Services University of Health Sciences, Bethesda, MD; Department of Medicine, The Ohio State University, Columbus, OH; IDEC Pharmaceuticals Inc, San Diego; and Genentech Pharmaceuticals, Inc, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-087629","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.bloodjournal462219"},{"key":"R2-087629","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"R4-087629","unstructured":"Rai  KR,   Peterson  B,   Elias  L,  et al:  A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia:   A CALGB, SWOG, CTG\/NCI-C, and ECOG intergroup study.   Blood 88:  141a,1996  (abstr 552)"},{"key":"R6-087629","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"R7-087629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"R8-087629","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"R9-087629","unstructured":"Coiffier  B,   Haioun  C,   Ketterer  N,  et al:  Rituximab for the treatment of patients with relapsing or refractory aggressive lymphoma:   A multicenter phase II study.   Blood Sep 15:  1927,1998-1932,"},{"key":"R10-087629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1851"},{"key":"R11-087629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R12-087629","doi-asserted-by":"crossref","unstructured":"Berinstein  N,   Grillo-Lopez  A,   White  CA,  et al:  Association of serum rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma.   Ann Oncol 9:  1,1998-7,","DOI":"10.1023\/A:1008416911099"},{"key":"R13-087629","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224"},{"key":"R14-087629","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01725.x"},{"key":"R15-087629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"R16-087629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3691"},{"key":"R17-087629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.791"},{"key":"R18-087629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1962"},{"key":"R19-087629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1567"},{"key":"R20-087629","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"R21-087629","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"R22-087629","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1997.17"},{"key":"R23-087629","unstructured":"Rojas  R,   Roman  J,   Torres  A,  et al:  Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage.   Leukemia 10:  1782,1996-1788,"},{"key":"R24-087629","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.1.213"},{"key":"R25-087629","unstructured":"Molica  S,   Vitelli  G,   Levato  D,  et al:  Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia.   Haematologica 84:  208,1999-211,"},{"key":"R26-087629","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4382.bloodjournal87104382"},{"key":"R27-087629","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"R28-087629","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"R29-087629","unstructured":"O\u2019Brien  SM,   Thomas  DA,   Freireich  EJ,  et al:  Rituxan has significant activity in patients with CLL.   Blood 94:  603a,1999  (abstr 2684)"},{"key":"R30-087629","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00305.x"},{"key":"R31-087629","doi-asserted-by":"crossref","unstructured":"Lagneaux  L,   Delforge  A,   Bron  D,  et al:  Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells.   Blood 9:  2387,1998-2396,","DOI":"10.1182\/blood.V91.7.2387"},{"key":"R32-087629","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"R33-087629","unstructured":"Pearson  MD,   Shinn  S,   Grever  MR,  et al:  Rituximab induces in vitro apoptosis in human chronic lymphocytic leukemia cells independent of complement mediated lysis but requires Fc\u03b3 receptor ligation.   Blood 94:  313a,1999  (abstr 4626)"},{"key":"R34-087629","doi-asserted-by":"crossref","unstructured":"Demidem  A,   Lam  A,   Alas  S,  et al:  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell  line to cell killing by cytotoxic drugs.   Can Chemo Radiopharm 12:  177,1997-180,","DOI":"10.1089\/cbr.1997.12.177"},{"key":"R35-087629","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01364.x"},{"key":"R36-087629","unstructured":"Perkins  JG,   Flynn  JM,   Byrd  JC:   Frequency and type of infections in fludarabine-refractory b-cell chronic lymphocytic leukemia and small lymphocytic lymphoma:   Implications for clinical trials in this patient population.   Blood 94:  540a,1999  (abstr 2412)"},{"key":"R37-087629","unstructured":"Venugopal  P,   Sivaraman  S,   Huang  X,  et al:  Up-regulation of CD20 expression in chronic lymphocytic leukemia cells by in vitro exposure to cytokines.   Blood 92:  247a,1998"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.8.2153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:31:38Z","timestamp":1653514298000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.8.2153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,15]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,4,15]]}},"alternative-id":["10.1200\/JCO.2001.19.8.2153"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.8.2153","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4,15]]}}}